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Abstract Dementias are the most common neurodegen-
erative diseases and they are increasingly becoming a
major public health problem. The most common form of
dementia, affecting over 20 million people worldwide, is
Alzheimer’s disease (AD). AD is a neurodegenerative
disease of the central nervous system mainly found in older
adults, with an incidence that increases with age. With the
development of newer technologies, including genetic
screening technologies and PET/MRI scanning, the role of
genetic studies and neuroimaging is being redefined;
indeed, these approaches are able to provide support not
only in the clinical diagnosis of dementia, but also in its
presymptomatic evaluation. Many researchers agree that
early identification of AD, before abnormal accumulation
of amyloid and tau proteins, could provide an opportunity
to hinder the progression of the disease. [18F]2-fluoro-2-
deoxy-D-glucose (FDG) PET studies have shown that
decreased glucose metabolism in AD precedes clinical
diagnosis and that the degree of clinical disability in AD
correlates closely with the magnitude of the reduction in
brain glucose metabolism. Data on presymptomatic muta-
tion carriers from families with known early-onset auto-
somal dominant AD (familial AD) show reductions in the
cerebral metabolic rate of glucose (CMRglc), consistent
with the expected AD PET pattern, in the absence of severe
atrophy on MRI. These results suggest that PET CMRglc
measures have the potential to serve as preclinical bio-
markers of dementia, useful also for tracking disease pro-
gression. This review highlights the role of genetics and
FDG PET in understanding the pathogenesis of dementia.
Keywords FDG PET  Dementia  Gene 
Alzheimer’s disease
Introduction
Dementias are the most common neurodegenerative diseases
and they are increasingly becoming a major public health
problem. These diseases are, in fact, one of the major causes
of disability in the general population and it is estimated that
their prevalence, currently standing at 35.6 million people
worldwide, will increase to 115 million by 2050 [1].
The most common form of dementia, affecting over 20
million people worldwide, is Alzheimer’s disease (AD). AD
is a neurodegenerative disease of the central nervous system
mainly found in older adults, with an incidence that
increases with age. From a clinical point of view, it is
characterized predominantly by initial deficits in episodic
memory, followed by progressive involvement of semantic
memory, attention, executive function and language skills.
Disease progression, lasting an average of 10 years, leads to
the death of the individual, usually due to intercurrent
infections. The key features of the AD brain are neuronal
and synapse loss, and the deposition of extracellular plaques
composed of amyloid-b (Ab) peptides and intraneuronal
neurofibrillary tangles consisting of hyperphosphorylated
tau protein.
Although the most frequent form is sporadic AD, the
rare autosomal and dominant early-onset form of AD
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(EOAD) has provided valuable insight into the disease
pathogenesis.
Most dementia cases are late onset and are probably
linked to both genetic and environmental factors. The
most common risk factors include brain injury, diabetes,
hypercholesterolemia and obesity. Moreover, recent
studies seem to indicate an involvement of cerebrovas-
cular risk factors in the development of a substantial
proportion of dementia cases. With regard to the possible
role of these risk factors in dementia, data (spanning 10
or 20 years) from large epidemiological studies conducted
in Minnesota, Illinois and Indiana and from a US national
study showed a substantial reduction in cognitive
impairment in the general population, measured using
neuropsychological tests, and thus justify cautious opti-
mism over the possible impact of reducing cerebrovas-
cular risk factors in dementia [2].
These data are also confirmed by the results of a Rot-
terdam study, which provided evidence of a reduction in
the incidence of dementia between 1990 and 2005 [3].
Many experts agree that identifying AD early, before
abnormal accumulation of amyloid and tau proteins, could
provide an opportunity to hinder the progression of the
disease.
A number of strategies under study were recently dis-
cussed at the 2012 annual meeting of the Society for
Neuroscience. Several neuroimaging techniques have been
included among the biomarkers of AD; however, scientific
evidence is still under development [4].
To develop preventive treatments for AD, it is necessary
to identify early biological markers that are predictive of
AD. To date, the best-recognized in vivo markers are
measures of brain structure and function, as obtained with
neuroimaging. The distribution, in the brain, of the PET
tracer [18F]2-fluoro-2-deoxy-D-glucose (FDG) reflects
regional glucose consumption, correlating with cerebral
synaptic activity [5]. Since neurodegenerative dementias
are characterized by synaptic and neuronal loss, FDG PET
is able to consistently reveal significant hypometabolism in
several cortical regions.
Brain volume loss as assessed on magnetic resonance
imaging (MRI), and reductions in the cerebral metabolic
rate of glucose (CMRglc) as measured with FDG PET are
sensitive to AD-related brain changes. A crucial question is
whether these brain measures can allow preclinical detec-
tion of dementia. To understand how AD starts and pro-
gresses, it is necessary to follow subjects through normal
aging to the onset of clinical symptoms. Several studies
have shown measures of brain atrophy directly assessed
using MRI techniques, capable of capturing presymptom-
atic changes in familial forms of AD [6–8].
FDG PET studies have shown that decreased glucose
metabolism in AD precedes clinical diagnosis and that the
degree of clinical disability in AD correlates closely with
the magnitude of the reduction in brain metabolism.
Recent studies have provided evidence of dynamic
changes in PET amyloid and FDG imaging at different
stages of AD [9]. In order to compare brain atrophy with
hypometabolism as preclinical markers of AD, several
studies have presented data on presymptomatic mutation
carriers from families with known early onset, autosomal
dominant AD, i.e. familial AD (FAD) [10]. Presymptom-
atic FAD individuals have been found to show CMRglc
reductions consistent with the expected AD PET pattern,
but in the absence of severe atrophy on MRI [11]. These
results suggest that PET CMRglc measures could poten-
tially serve as preclinical biomarkers of dementia, useful
also for tracking disease progression.
New diagnostic criteria
A few years ago, the results of many years of research
allowed an update of the clinical research criteria for
dementia and the refinement of guidelines (originally con-
ceived around two and a half decades earlier) for diagnosis
of the various forms of dementia [12]. Meanwhile, 2011
saw the publication of recommendations, from the National
Institute on Aging–Alzheimer’s Association workgroups,
on diagnostic guidelines for Alzheimer’s disease [13].
These new recommendations are the result of acquisitions
obtained through both laboratory and clinical research.
The new criteria proposed a common lexicon for the
clinical and research sectors [12], which has generated
much debate in the scientific community [14–16]. Devel-
opments in the field of biomarkers and the use, alongside
traditional genetics, of new more specific and more sensi-
tive techniques were crucial for the development of these
new criteria, but also for redefining frontotemporal
dementia (FTD) and its subtypes.
Guidelines on the diagnosis and management of
dementia disorders recently developed by a European
Federation of Neurological Societies (EFNS) study group
on dementia, which took into consideration the canonical
syndromes and molecular genetic aspects, identify a
number of different clinical forms of dementia with dif-
ferent ages at onset and/or durations [17].
Moreover, in accordance with recent EFNS-ENS
guidelines on the use of neuroimaging in the diagnosis of
dementia [18], structural imaging should be performed to
exclude other potentially treatable diseases, to detect vas-
cular lesions, and to identify specific findings to help dis-
tinguish between different forms of neurodegenerative
dementia.
Neuroimaging is recommended in cases in which the
diagnosis remains in doubt. Amyloid imaging is likely to
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prove clinically useful in several fields, including the
evaluation of atypical AD presentations [18].
Biomarkers
Recent years have provided some important developments
in the field of dementia, fundamental in furthering under-
standing of the pathogenetic mechanisms of the disease. It is
now believed that AD pathophysiology started years before
cognitive changes are detected and probably before the
onset of clinical signs of dementia [19, 20]. Hence, there has
emerged an urgent need for reliable diagnostic biomarkers
able to detect the disease in a presymptomatic stage. Recent
studies have focused on imaging markers or cerebrospinal
fluid (CSF) and blood biomarkers for early diagnosis.
The biomarkers currently used for AD are both genetic,
such as the pathogenetic mutations in three candidate genes
(amyloid-b precursor protein, APP; presenilin 1, PS1;
presenilin 2, PS2) and biochemical (amyloid-b and tau
proteins in the CSF) [21]. Moreover, the biomarkers of
neurodegeneration include neuroimaging correlates of
hippocampal atrophy on structural MRI and symmetric
decreased metabolism in the temporoparietal regions on
FDG PET.
The 11C Pittsburgh compound (PiB) has always been the
most validated tracer for imaging amyloid pathology.
However, there is now a new tracer, 18F-florebetapir that,
thanks to the longer half-life of the radioactive isotope 18F
(110 versus 20 min for the 11C of 11C-PiB), has the
potential to be used even more extensively both for clinical
and research purposes [22].
In a 2003 study involving a family carrying the T122R
mutation in PS2 and showing an atypical presentation of
dementia, all the biomarkers (the functional neuroimaging
investigations, CSF levels of Ab 1-42, and Tau protein)
provided evidence indicating future dementia development
[23].
Today, FDG PET has moved from the research arena
into clinical practice. Amyloid imaging allows earlier
diagnosis of AD and better differential diagnosis of
dementia and it also provides prognostic information for
mild cognitive impairment (MCI) [24].
The genetics of dementia
The genetic approach to the study of neurodegenerative
diseases is undoubtedly the one that has provided and
continues to provide the most significant contribution to
understand the various aspects of these disorders: their
pathogenesis and diagnosis, the therapeutic options, and
the important ethical implications.
A search of the PubMed database using keywords such as
‘‘dementia’’ and ‘‘genetic’’ reveals, to date, more than
25,000 papers, almost half of which were published in the
past 6 years. The earliest paper, published in 1952, concerns
research into the genetics of AD and Pick’s disease [25];
one of the most recent contributions is a large collaborative
genome-wide association (GWA) study that highlights a
new AD locus on chromosome 10 [26]. The list of genetic
mutations associated with autosomal dominant forms of
familial dementia is getting longer and longer [27].
The extensive study of the genetics of dementia led to
the development of a molecular classification of different
forms of dementia and now many groups are working to
establish the possible diagnostic utility, in dementia, of the
biological and genetic biomarkers developed [28].
The genetics of AD
Alzheimer’s disease is a genetically complex, multifacto-
rial disease involving many candidate genes [29]. From a
genetic point of view, AD can be divided into two different
forms: FAD and sporadic AD. Apart from the fact that
FAD often has onset at an earlier age and can present some
neurological characteristics not generally present in the
sporadic form, the two subtypes are clinically indistin-
guishable. AD can also be divided into two groups by age
at onset: early onset (onset \65 years; EOAD) and late
onset (onset [65 years; LOAD).
In rare early-onset FAD, different disease-causing
mutations have been described. At the time of writing, the
Alzheimer Disease & Frontotemporal Dementia Mutation
Database lists a total of 231 different fully penetrant
autosomal dominant mutations in 517 families around the
world (http://molgen-www.uia.ac.be/ADMutations/).
These mutations are located in three genes (i.e. APP, PS1,
PS2) that have been shown to cause 50 % of all FAD. In
particular, 33 pathogenetic mutations for APP, 185 for PS1
and 13 for PS2 have been discovered [30, 31].
In the more common sporadic form, a locus on chro-
mosome 19, coding for apolipoprotein E (ApoE), has been
associated with increased susceptibility. In particular,
genetic and epidemiological studies have identified the
epsilon 4 (e4) allele as a major risk factor for the disease,
being associated with an increased risk of developing the
disease and with a lower age at onset [32].
The ApoE e4 allele is the only confirmed factor involved
in genetic susceptibility to AD, but it is neither necessary
nor sufficient to cause the disease [33]. Moreover,
according to recent data, the ApoE could be a major gene
with semi-dominant inheritance (individuals with a double
dose of the e4 allele have a 35-fold increased risk of
developing the disease) [34].
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The ApoE e4 isoform is thought to interact with the
mechanisms associated with aging, resulting in deposition
in the brain, of aggregated deposits of abnormal proteins;
this impairs neurotransmission, thereby hastening the dis-
ease process [35, 36]. However, over 70 % of all cases in
the general population are associated with this gene, which
suggests that numerous other factors, in addition to genetic
predisposition, must together contribute to determining the
disease [37].
In recent years, the search for other genetic factors has
shown associations with polymorphisms in an increasing
number of genes, all possibly involved, by interfering with
the deposition and clearance of Ab in the disease patho-
genesis [38].
Recent progress in genomic methodology and the
availability of large sample sizes have ushered in the era of
GWA studies.
From 2005 to the present, many GWA studies have been
published and thanks to these studies; several loci associ-
ated with various neurodegenerative diseases have been
identified.
According to the AlzGene database, GWA studies have
identified ten novel loci associated with an increased risk of
developing AD, i.e. BIN1, CLU, ABCA7, CR1, PICALM,
MS4A6A, MS4A4E, CD33, CD2AP and EPHA1 [39–42].
The role of all the new genes in the pathogenesis of AD
is supported by their involvement in the pathogenetic
processes related to neurodegeneration, including the
amyloidogenic cascade, tau hyperphosphorylation, apop-
tosis, oxidative stress, cholesterol and lipid metabolism,
and immune inflammatory processes.
Despite these successes, this type of approach has many
limitations because these associations do not have a high
predictive value and may also lead to the identification of
false positives and false negatives. For this type of
approach, studying a very large number of subjects is
necessary. In fact, whereas several thousand individuals are
needed to describe an association with a rare, high-impact
variant, the description of a common variant with a low
effect requires many thousands of cases and controls [43].
For this purpose, international research groups have
organized specific genetic consortia, thus making large
collaborative studies feasible.
During 2011, thanks to a group of international
researchers, the First International Collaboration on the
Genetics of Alzheimer’s Disease was established with a
view to perform collaborative studies on large numbers of
subjects (International Genomics of Alzheimer’s Project).
Recent GWA studies have identified CLU, CR1, ABCA7
BIN1, PICALM and MS4A6A/MS4A6E in addition to the
long-established ApoE as loci for AD [39–42, 44].
New findings have recently provided fresh insight into
the genetic mechanisms underlying the development of
AD.
Starting from the hypothesis that low-prevalence vari-
ants showing moderate to high effect may be associated
with AD risk, two independent research groups [45, 46]
have shown that a rare variant (rs 75932628 encoding an
arginine to histidine substitution at residue 47, R47H) in
the TREM2 gene, encoding the triggering receptor
expressed on myeloid cells on chromosome 6 (6p21.1-
q15), is significantly associated with increased suscepti-
bility to LOAD.
Another recent study has provided evidence that a low-
frequency variant of the coding mutation (A673T) in the
APP gene protects against AD and cognitive decline in the
elderly without AD [47, 48]. The discovery of the protec-
tive effect of the A673T substitution against AD provides
proof of the principle that reducing the b-cleavage of APP
may protect against the disease, and supports the clinical
usefulness of the current amyloid-directed therapeutic
research efforts.
The recent important characterizations of the novel risk
factor TREM2 and the novel protective APP-related variant
displaying a statistically significant association with AD
provide grounds for cautious optimism regarding the
results of genetic research.
It has been suggested that families need clinical guide-
lines to help them navigate the complexities of dementia
(in particular AD and FTD) genetics and the processes of
genetic testing and counseling [49].
In fact, the diagnosis of progressive disease in a clin-
ically healthy individual is a new but increasingly fre-
quent scenario for the neurologists and geneticists [50],
and it is one that carries ethical implications [51] and
underlines the importance of genetic counseling. The
genetic approach, being able to shed light on the patho-
genetic mechanisms of the disease and thus indicate
possible therapeutic avenues, is important both from a
research and a clinical perspective. For example, a recent
study aiming to investigate whether treatment with human
anti-Ab monoclonal antibodies leads to a measurable
reduction in the level of Ab in the brain and to elucidate
the mechanism of amyloid reduction provided data on the
use of an amyloid-eating drug that removes plaque
through phagocytosis [52].
As pointed out by a recent editorial in Neurology [53], it
is recommended to start treating patients before the disease
becomes symptomatic, i.e. to exploit the window, in the
preclinical stages of the disease, in which CSF and PET
biomarkers correlated with amyloidogenic and neurode-
generative processes are significantly altered.
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FDG PET and the genetics of AD
The link between genetic susceptibility and AD could be
elucidated by the association of AD candidate genes with
alterations in brain functions, which can be assessed by
FDG PET.
Several studies support the use of FDG PET as an AD
biomarker and, furthermore, as an endophenotype for the
assessment of genetic risk factors for AD.
FDG PET undoubtedly has many advantages; however,
it could also have some limitations. First of all, metabolism
studies are not able to provide information about the
pathophysiological mechanisms linking genetic variability
to AD susceptibility. In addition, CMRglc is also pre-
sumably subject to multiple genetic regulations and
affected by environmental factors.
However, despite these limitations, FDG PET deserves
to be considered a presymptomatic AD endophenotype,
and several studies have already successfully used FDG
PET to reveal CMRglc alterations in normal individuals
who have a genetic risk of developing AD.
FDG PET and presymptomatic early-onset FAD
Studies of individuals from families with FAD with known
genetic mutations have provided unique information about
preclinical AD-related brain impairment and they consti-
tute an ideal resource for exploring the relationship
between genetic and phenotypic expression of the disease.
Several FDG PET studies on presymptomatic FAD sub-
jects showed the presence of regional parieto-temporal,
posterior cingulate cortex (PCC) and medial temporal lobe
hypometabolism on a background of wide-spread global
CMRglc impairment (Fig. 1) [11, 54, 55].
In particular, a previous FDG PET study on presymp-
tomatic at-risk individuals carrying the rare APP mutations
(compared to individuals without mutations) reported the
presence of parieto-temporal hypometabolism, with addi-
tional frontal deficits [56]. Similarly, a recent FDG PET
study conducted on carriers of the PS2 mutation demon-
strated CMRglc reductions in parietal and precuneus
regions, showing progression at follow-up in parieto-tem-
poral and frontal lobes [57].
Interestingly, an FDG PET study of presymptomatic
PS1 mutation carriers provided definitive evidence that
CMRglc reductions precede not only clinical symptoms but
also structural brain changes, showing cortical and medial
temporal lobe metabolic reductions, occurring before and
exceeding structural brain atrophy observed on MRI. After
partial volume correction, CMRglc reductions ranged from
13 % (whole brain) to 21 % (PCC), reflecting true reduc-
tions in brain glucose utilization per unit brain volume;
after partial volume correction, the medial temporal lobe
CMRglc values were reduced to 12 % in the hippocampus
and 20 % in the entorhinal cortex [11].
These findings are consistent with and could be
explained by the AD pathological cascade model: follow-
ing the initial deposition of amyloid plaques, the dominant
process is represented by neuronal and synaptic dysfunc-
tion, which could be studied using FDG PET. The neuronal
loss that ultimately causes atrophy measurable with MRI
appears only later [58].
FDG PET and ApoE-associated genetic risk
The e4 allele of the ApoE gene is a widely recognized
genetic risk factor for AD and the association between the
ApoE e4 allele and AD risk has been reported in hundreds
of studies. The ApoE e4 genotype is considered a risk
factor since almost 40 % of LOAD patients have at least
one ApoE e4 allele; moreover, a copy of the e4 allele is
found in about 25 % of Americans and in 33 % of those
with a reported family history of dementia in a first-degree
relative. Two copies of the e4 allele are found in 2–3 % of
Americans and about 5 % of those with a reported history
of dementia in a first-degree relative [59].
To date, many FDG PET studies have been published,
examining the effect of the presence of the ApoE e4 allele
on CMRglc and confirming, study after study, the associ-
ation between metabolic impairment, assessed by FDG
PET, and AD genetic risk factors in cognitively normal
subjects. FDG PET studies in non-demented individuals
report that, as compared to e4 non-carriers, ApoE e4
homozygotes (therefore, with a particularly high risk of
developing AD) have a significantly reduced CMRglc in
the same brain regions as clinically affected AD patients,
including the posterior cingulate/precuneus, parietal, tem-
poral and prefrontal regions [59]. As compared to e4 non-
carriers, ApoE e4 heterozygotes show similar, but milder,
hypometabolism within the same brain regions found to be
affected in AD patients and in ApoE e4 homozygotes [59–
62]. There is evidence that the metabolic reductions in
ApoE e4 carriers are more progressive (25 % decline in
CMRglc over a two-year interval) and correlate with the
reductions in cognitive performance [63].
Moreover, CMRglc abnormalities have been detected
even earlier, in 20- to 40-year-old ApoE e4 carriers [64],
making them the earliest brain abnormalities yet found in
living subjects at risk of AD, detected many years before
the estimated median age of dementia onset in e4
heterozygotes.
The ApoE e4 allele also contributes to heterogeneity in
MCI patients by regionally affecting brain metabolic
activity, so that MCI ApoE e4 carriers present a more
extensive CMRglc impairment than non-carriers, reflecting
the known ApoE e4-related increased vulnerability to
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dementia [65]. In particular, the hypometabolism usually
found in parietotemporal and temporal regions in MCI
patients extended to the frontal and anterior cingulate
cortex in MCI ApoE e4 carriers. A recent study showed a
differential effect of ApoE genotype on amyloid load and
glucose metabolism in AD patients [66], confirming earlier
reports.
FDG PET and maternal family history of AD
FDG PET studies have also proved to be useful in esti-
mating the increased risk of future AD in another cogni-
tively normal at-risk population, namely subjects with a
maternal family history of AD. Indeed, recent reports
provided evidence for phenotypic CMRglc differences
between cognitively normal individuals with a maternal,
paternal or negative family history of AD [67], even pre-
ceding the structural brain abnormalities observed on MRI
[68]. In particular, individuals with a maternal history of
AD were found to show CMRglc reductions in typically
AD-vulnerable brain regions, namely the parietotemporal,
posterior cingulate/precuneus, medial temporal and pre-
frontal cortices, as compared to individuals with no family
history and those with an AD-affected father [67]. The
hypometabolism occurred within the group of maternal AD
subjects independently of the subject’s age, gender, years
of education and ApoE genotype.
Over a two-year follow-up, CMRglc impairment in
maternal AD individuals was found to be progressive [69],
with longitudinal CMRglc reductions in the posterior cin-
gulate/precuneus, parietotemporal and frontal cortices. In
contrast, individuals with an AD-affected father and those
Fig. 1 FDG PET scans (first
row) and MRI co-registration of
two preclinical early-onset FAD
siblings with the APP 717 Val-
Ile mutation. Case 1 a 60-year-
old male with deficits in short-
and long-term memory and in
visuospatial and executive
functions showed mild parietal
and hippocampal atrophy
associated with severe parietal
hypometabolism and moderate
CMRglc reductions in the
frontal cortex and hippocampus.
Case 2 a 48-year-old female
showed only long-term memory
deficits and no significant
atrophy on the MRI scan.
However, the FDG PET scan
demonstrated the presence of
mild parietal and inferior frontal
hypometabolism (arrows
indicate the hypometabolism)
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with no family history of AD showed longitudinal CMRglc
reductions only in the frontal cortex, which is a typical
effect of aging.
FDG PET and the KIBRA gene
KIBRA is a cytoplasmic protein that is highly expressed in
the brain and is a binding partner of dendrin, a putative
modulator of synaptic plasticity. There are two allelic
variants of the KIBRA gene (T and C), resulting in three
possible genotypes: TT, CT and CC. GWA studies and
several replication studies [70, 71] demonstrated that KI-
BRA T allele non-carriers (CC genotype) had lower epi-
sodic memory performance compared to KIBRA T carriers
(CT and TT genotypes).
Since memory impairment is the cardinal clinical fea-
ture of AD, the next step was to investigate the possibility
of an association between AD and KIBRA. Corneveaux and
colleagues [72] tested this hypothesis using data from FDG
PET, as an endophenotype. KIBRA T non-carriers showed
significant CMRglc reductions, compared to KIBRA T
carriers, in the same brain regions preferentially affected
by AD, including the precuneus and PCC.
These FDG PET findings provide a foundation for a
common molecular mechanism contributing not only to
successful episodic memory performance but also to the
predisposition to AD, opening possible future perspectives
for memory-enhancing, AD-modifying and AD risk-
reducing therapies.
Genetics of FTD
First described over 100 years ago, today we can refer to
several clinical forms and at least 16 different pathological
subtypes of FTD [73].
FTD refers to a disease spectrum including the behav-
ioral variant FTD (bvFTD), primary progressive aphasia
(PPA), progressive supranuclear palsy/corticobasal degen-
eration syndrome (PSP/CBDS), and FTD with amyotrophic
lateral sclerosis (FTD-ALS).
The international consortia for the two main syndromes,
bvFTD and PPA, have recently revised the diagnostic cri-
teria and published consensus criteria [74, 75], including
neuroimaging and genetics.
The first evidence of a genetic cause of familial FTD
was provided 18 years ago with the demonstration of a
linkage to chromosome 17 in a familial form with auto-
somal dominant parkinsonism [76]; the most recent evi-
dence is a GGGGCC expansion in C9orf72, a major cause
of FTD and ALS [77, 78].
To date, the familial forms of FTD [79] are explained by
the seven genes (C9orf72, CHMP2B, FUS, GRN, MAPT,
TARDBP, VCP), in which 193 pathogenetic mutations have
been described (http://www.molgen.ua.ac.be/ADMutations).
All the genes code for a protein including C9orf72 [80], an
open reading frame coding for a protein recently character-
ized and located on chromosome 9p21 [77, 78, 80]. The most
revolutionary finding on the genetics of FTD is that these
mutations and expansions concern a very high percentage of
families in the world. Indeed, there are now more than
900 families in the world with mutations associated with
FTD. A flow chart for FTD genetic testing was recently
published [81].
There also exist phenotypic characterizations of FTD
linked to the mutations in GRN and C9orf72 and in which
an important contribution is made by neuroimaging [82]. In
particular, a study in monozygotic twins carrying a 4-bp
deletion (c.388_391delCAGT) in exon 4 of GRN reported
strong clinical, neuroimaging, and serum progranulin level
similarities, demonstrating the importance of shared
genetic profiles beyond environmental influences in the
symptomatic expression of the disease [82]. In a recent
case report, brain FDG PET demonstrated mild hypome-
tabolism involving the medial frontal and lateral temporal
lobes, the left more than the right, which progressed over
time. This case was subsequently confirmed to have the
C9orf72 expansion, thus highlighting the need to consider
mutations in the FTD-associated genes when a familial
disorder is suggested and neuroimaging studies reveal
findings atypical of an AD pathophysiological process,
despite the typical anterograde amnesic syndrome [83].
Different research centers worldwide are involved in
the genetic approach to FTD. The work of GENFI
(http://www.ucl.ac.uk/drc/research/current-studies/genfi), a
multicenter collaborative consortium for tracking the evo-
lution of genetic FTD and its associated disorders from
their earliest stages, is ongoing.
The main aim of GENFI is to recruit and follow a well-
characterized and uniformly studied cohort of individuals
affected with or at risk of developing the major genetic
forms of FTD with mutations in the MAPT or GRN genes
or expansions in the C9orf72 gene.
The innovative aim of the consortium is to derive
sample size estimates and outcome measures for future
natural history studies and clinical trials of disease-modi-
fying therapies.
Conclusions
Several studies describe the contribution made by FDG
PET and genetics to understand the pathogenesis of
dementia. The reported data on presymptomatic mutation
carriers from families with known early-onset autosomal
dominant AD (FAD) show reductions in the cerebral
Clin Transl Imaging (2013) 1:235–246 241
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glucose metabolism consistent with the typical AD PET
pattern.
These reported results indicate that PET brain metabolic
measures have a potential role to play as preclinical bio-
markers for genetic dementia and for tracking disease
progression.
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